CAR T-Cell Therapy Scores Again in DLBCL – MedPage Today
FierceBiotech |
CAR T-Cell Therapy Scores Again in DLBCL
MedPage Today ATLANTA — The success of CAR T-cell therapy continues to grow, as tisagenlecleucel (Kymriah), already approved for a type of leukemia, achieved durable responses in half of patients with refractory diffuse large B-cell lymphoma (DLBCL). Results of a … New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients |
